Medtronic Reporting Stents Met Primary Endpoint, No Statistically Significant Raises in ARC Occurrence
October 31, 2013 at 12:37 PM EDT
According to findings from several studies presented at the 25^th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, patients with coronary artery disease who received an Endeavor or Resolute drug-eluting stent from Medtronic, Inc. (NYSE: MDT ) and subsequently interrupted their dual antiplatelet therapy (DAPT) earlier than current guidelines recommend experienced no increased risk of
